
CalciMedica Inc (CALC) Stock Forecast & Price Target
CalciMedica Inc (CALC) Analyst Ratings
Bulls say
CalciMedica Inc. is advancing its lead product candidate, Auxora, which has demonstrated a significant clinical benefit in reducing mortality rates in patients with acute kidney injury (AKI) associated with severe COVID-19 pneumonia, reporting a 62.7% relative reduction in mortality at day 30. The ongoing KOURAGE Phase 2 trial, focused on evaluating Auxora's effectiveness for AKI with acute hypoxemic respiratory failure, stands to further bolster the company's prospects for adoption given the potential benefits, including decreased need for dialysis and improved renal recovery. The promising outcomes observed in the CARDEA trial, particularly for the AKI subgroup, underline Auxora's potential to establish itself as a critical therapeutic option in treating serious inflammatory and immunologic diseases.
Bears say
CalciMedica's financial outlook appears negative due to the potential for failed or inconclusive clinical trials, which can significantly hinder the development of its product candidates. The company also faces challenges in securing adequate funding to progress its drug, Auxora, through necessary stages of development, raising concerns about its financial viability. Additionally, the recent announcement of a first-quarter 2025 earnings per share (EPS) of ($0.36), which fell short of both estimates and consensus expectations, underscores ongoing operational difficulties that could further impact investor confidence.
This aggregate rating is based on analysts' research of CalciMedica Inc and is not a guaranteed prediction by Public.com or investment advice.
CalciMedica Inc (CALC) Analyst Forecast & Price Prediction
Start investing in CalciMedica Inc (CALC)
Order type
Buy in
Order amount
Est. shares
0 shares